REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update ...

Extensive peering and network path optimization via NewEdge Route Control enable a fast, seamless digital experience for business-critical AI applicationsSANTA CLARA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Netskope (NASDAQ: NTSK), a leader in modern security and networking for the cloud and AI era, today announced NewEdge AI Fast Path, a set of capabilities that efficiently optimize network paths to critical AI destinations, including AI applications hosted in public, private, or neo-clouds. Available no ...

CAMARILLO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Salem Media (OTCQX: SALM) announced today that it has posthumously presented the 2026 Stuart Epperson Award for Excellence in Christian Media to Dr. John Fullerton MacArthur Jr., honoring more than five decades of faithful Gospel ministry and global impact through Christian media. The award was presented during a private gathering at the 2026 National Religious Broadcasters (NRB) Convention, recognizing Dr. MacArthur as the fourth recipient of the honor. ...

GLDY is now live on app.streamex.com as investor onboarding and purchases commenceWINTER PARK, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. (“Streamex”) (NASDAQ: STEX), a commodity focused digital asset and real-world asset tokenization company, today announced that GLDY is now live and available for purchase on app.streamex.com. Henry McPhie, Co-Founder & Chief Executive Officer of Streamex, said: “Today marks an important milestone for Streamex, GLDY is now officially live and available to inves ...

OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026. The su ...

CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, f ...

采用云原生 Mavenir BSS 和核心网，与 TextNow 聚焦长期创新的战略相契合旧金山和德克萨斯州理查森市, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 美国领先的广告支持型免费无线服务提供商 TextNow 与颠覆性云原生电信技术提供商 Mavenir 今日宣布，将 Mavenir 的云原生 BSS 和核心网 (Core) 集成到 TextNow 的移动虚拟网络运营商 (MVNO) 基础设施中。 Mavenir 的云原生 BSS 和核心网平台解决方案旨在帮助 TextNow 更快地接纳新用户、推出差异化的服务层级，并扩展其免费无线模式，以覆盖更多正在寻求优质无线服务而又不愿支付过高费用的数百万美国民众。 此次与 Mavenir 的集成突显了 TextNow 对创新的关注，它提供了一系列功能来更好地支持 TextNow 超过 800 万的活跃用户，包括管理赞助合作伙伴、发展漫游合作关系以及为用户配置独立 SIM 卡档案的能力。 TextNow 合作与创新高级副总裁 Tristan Huntington 表示：“TextNow 花了 17 年时间证明，无线服务可以是免费的，可以 ...

Core Viewpoint - Euroseas Ltd. reported strong financial results for the fourth quarter and full year of 2025, highlighting high profitability and robust charter rates, while also addressing challenges in the containership market [4][5][6]. Fourth Quarter 2025 Financial Highlights - Total net revenues reached $57.4 million, a 7.7% increase from $53.3 million in Q4 2024, driven by higher average time charter rates despite a decrease in the average number of vessels operated [9][12]. - Net income for the quarter was $40.5 million, compared to $24.4 million in Q4 2024, with earnings per share of $5.82 (basic) and $5.79 (diluted) [7][23]. - The average time charter equivalent rate for the quarter was $30,268 per day, up from $26,479 per day in the same period last year [12][41]. - Adjusted EBITDA for Q4 2025 was $40.7 million, an increase from $32.8 million in Q4 2024 [11][22]. Full Year 2025 Highlights - Total net revenues for 2025 were $227.9 million, a 7.0% increase from $212.9 million in 2024, attributed to a higher number of vessels and increased charter rates [25]. - Net income for the year was $137.0 million, up from $112.8 million in 2024, with earnings per share of $19.73 (basic) and $19.72 (diluted) [36]. - The average time charter equivalent rate for the year was $29,107 per day, compared to $28,054 per day in 2024 [25][41]. - Adjusted EBITDA for the full year was $155.9 million, compared to $135.8 million in 2024 [35]. Fleet and Charter Coverage - The company has a charter coverage of approximately 87% for 2026 and over 71% for 2027, with contracted revenues exceeding $550 million over the next five years [5][6]. - The fleet operated an average of 22.22 vessels in 2025, compared to 21.73 vessels in 2024 [25][41]. Market Conditions and Challenges - The containership market faces challenges such as high orderbook levels in large containership segments and potential reductions in demand due to resumed traffic through the Suez Canal [6]. - Euroseas operates in the feeder and intermediate size vessel segments, which are expected to see a contraction in supply, benefiting modern vessel owners [6]. Shareholder Returns - The company declared a quarterly dividend of $0.75 per share for Q4 2025, reflecting a 7% increase and providing an annualized yield of about 5% [8]. - As of February 25, 2026, the company repurchased 480,455 shares, representing about 6.8% of outstanding shares, under a $20 million share repurchase plan [7].

Core Insights - Intelligent Bio Solutions Inc. has successfully received and deployed its first shipment of Intelligent Fingerprinting Drug Screening Readers through a partnership with Syrma Johari, marking a significant step in scaling production capacity and validating the operational and financial benefits of the collaboration [1][3] - The partnership is expected to deliver annual production cost savings of over 40%, leading to an anticipated improvement of approximately 20 percentage points in gross margin annually [1][3] - The company has doubled its in-house production capacity for lateral flow test strips, enhancing vertical integration and accelerating research and development [1][4] Production and Manufacturing - The first shipment of readers is being deployed across key customer verticals such as construction, transportation, logistics, and manufacturing in the U.K. and Europe, supporting growing commercial demand [2] - The partnership with Syrma Johari has provided access to manufacturing capacity approximately four times greater than prior capabilities, allowing for accelerated fulfillment and cost savings [3] - The company has sourced advanced manufacturing equipment that has doubled its in-house production capacity for lateral flow test strips, improving margins and reducing lead times [4] Strategic Positioning - The successful deployment of the first shipment and increased production capacity positions the company to enter the U.S. market with operational strength and the ability to grow with demand [5] - The company is building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion and accelerates innovation [5] - Additional production shipments are expected throughout 2026 as the company continues to build inventory and expand its commercial footprint [5] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [6] - The system is designed to screen for recent drug use in workplace settings, providing results in under ten minutes, which is valuable for employers in safety-critical industries [6] - Current customer segments outside the U.S. include construction, manufacturing, transport, logistics, mining, drug treatment organizations, and coroners [6]

Core Viewpoint - A class action lawsuit has been filed against Navan, Inc. for allegedly misleading investors regarding its IPO documents, particularly concerning undisclosed increases in sales and marketing expenses [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who acquired Navan shares from October 28, 2025, to February 23, 2026, including during the IPO [1][2]. - Investors have until April 24, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Financial Impact - Navan's shares have seen a significant decline, trading as low as $9.01 per share, which represents a drop of over 60% from the IPO price of $25 per share [3]. - The decline in share price has resulted in substantial losses for investors as the true state of the company's business was revealed [3]. Group 3: Company Overview - Navan, headquartered in Palo Alto, California, specializes in booking and expense reporting software for business travelers [2].